User menu

Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT)

Bibliographic reference Paul, C ; Puig, L ; Kragballe, K ; Luger, T ; Lambert, J ; et. al. Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT). In: British Journal of Dermatology, Vol. 170, no.2, p. 425-434 (2014)
Permanent URL
  1. Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, Bos JD, Burmester G-R, Chimenti S, Dubertret L, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, Hönigsmann H, Hussain M, Jobling R, Karvonen S-L, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne J-P, Orzechowski H-D, Rantanen T, Reich K, Reytan N, Richards H, Thio HB, van de Kerkhof P, Rzany B, European S3-Guidelines on the systemic treatment of psoriasis vulgaris, 10.1111/j.1468-3083.2009.03389.x
  2. Leonardi Craig L, Kimball Alexa B, Papp Kim A, Yeilding Newman, Guzzo Cynthia, Wang Yuhua, Li Shu, Dooley Lisa T, Gordon Kenneth B, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1), 10.1016/s0140-6736(08)60725-4
  3. Papp Kim A, Langley Richard G, Lebwohl Mark, Krueger Gerald G, Szapary Philippe, Yeilding Newman, Guzzo Cynthia, Hsu Ming-Chun, Wang Yuhua, Li Shu, Dooley Lisa T, Reich Kristian, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2), 10.1016/s0140-6736(08)60726-6
  4. Strober Bruce E., Poulin Yves, Kerdel Francisco A., Langley Richard G., Gu Yihua, Gupta Shiraz R., Okun Martin M., Papp Kim A., Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study, 10.1016/j.jaad.2010.03.009
  5. Krueger Gerald G., Langley Richard G., Leonardi Craig, Yeilding Newman, Guzzo Cynthia, Wang Yuhua, Dooley Lisa T., Lebwohl Mark, A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis, 10.1056/nejmoa062382
  6. Reich K., Puig L., Paul C., Kragballe K., Luger T., Lambert J., Chimenti S., Girolomoni G., Nicolas J.-F., Rizova E., Brunori M., Mistry S., Bergmans P., Barker J., , One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis, 10.1111/bjd.12643
  7. European Medicines Agency Ustekinumab. Summary of Product Characteristics
  8. FINLAY A.Y., KHAN G.K., Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use, 10.1111/j.1365-2230.1994.tb01167.x
  9. EuroQol - a new facility for the measurement of health-related quality of life, 10.1016/0168-8510(90)90421-9
  10. Zigmond A. S., Snaith R. P., The Hospital Anxiety and Depression Scale, 10.1111/j.1600-0447.1983.tb09716.x
  11. Cardiff University Dermatology Life Quality Index (DLQI) 2012
  12. EuroQol Group Measuring self-reported population health: an international perspective based on EQ-5D 2004
  13. Bjelland Ingvar, Dahl Alv A, Haug Tone Tangen, Neckelmann Dag, The validity of the Hospital Anxiety and Depression Scale, 10.1016/s0022-3999(01)00296-3
  14. Opel, J Drugs Dermatol, 11, 1498 (2012)
  15. De Jong E.M.G.J., Mork N. J., Seijger M.M.B., De La Brassine M., Lauharanta J., Jansen C.T., Guilhou J.J., Guillot B., Ostrojic A., Souteyrand P., Vaillant L., Barnes L., Rogers S., Klaber M.R., Van De Kerkhof P.C.M., The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: results of a multicentre placebo-controlled randomized trial, 10.1046/j.1365-2133.2003.05173.x
  16. Griffiths Christopher E.M., Strober Bruce E., van de Kerkhof Peter, Ho Vincent, Fidelus-Gort Roseanne, Yeilding Newman, Guzzo Cynthia, Xia Yichuan, Zhou Bei, Li Shu, Dooley Lisa T., Goldstein Neil H., Menter Alan, Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis, 10.1056/nejmoa0810652
  17. European Medicines Agency. Methotrexate Summary of Product Characteristics
  18. Berth-Jones J., Thompson J., Papp K., , A study examining inter-rater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index, 10.1111/j.1365-2133.2008.08680.x
  19. Gourraud Pierre-Antoine, Le Gall Caroline, Puzenat Eve, Aubin François, Ortonne Jean-Paul, Paul Carle F., Why Statistics Matter: Limited Inter-Rater Agreement Prevents Using the Psoriasis Area and Severity Index as a Unique Determinant of Therapeutic Decision in Psoriasis, 10.1038/jid.2012.124
  20. McInnes Iain B, Kavanaugh Arthur, Gottlieb Alice B, Puig Lluís, Rahman Proton, Ritchlin Christopher, Brodmerkel Carrie, Li Shu, Wang Yuhua, Mendelsohn Alan M, Doyle Mittie K, Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial, 10.1016/s0140-6736(13)60594-2
  21. Reich K., Langley R.G., Lebwohl M., Szapary P., Guzzo C., Yeilding N., Li S., Hsu M-C., Griffiths C.E.M., Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies : Cardiovascular safety of ustekinumab in clinical trials of psoriasis, 10.1111/j.1365-2133.2011.10257.x
  22. Heller Misha M., Wong Jillian W., Nguyen Tien V., Lee Eric S., Bhutani Tina, Menter Alan, Koo John Y.M., Quality-of-Life Instruments: Evaluation of the Impact of Psoriasis on Patients, 10.1016/j.det.2011.11.006
  23. Mrowietz U., Kragballe K., Reich K., Spuls P., Griffiths C. E. M., Nast A., Franke J., Antoniou C., Arenberger P., Balieva F., Bylaite M., Correia O., Daudén E., Gisondi P., Iversen L., Kemény L., Lahfa M., Nijsten T., Rantanen T., Reich A., Rosenbach T., Segaert S., Smith C., Talme T., Volc-Platzer B., Yawalkar N., Definition of treatment goals for moderate to severe psoriasis: a European consensus, 10.1007/s00403-010-1080-1
  24. National Institute for Health and Care Excellence Ustekinumab for the treatment of adults with moderate to severe psoriasis 2009
  25. Khilji, Br J Dermatol, 147, 50 (2002)
  26. Hongbo Yan, Thomas Charles L., Harrison Michael A., Sam Salek M., Finlay Andrew Y., Translating the Science of Quality of Life into Practice: What Do Dermatology Life Quality Index Scores Mean?, 10.1111/j.0022-202x.2005.23621.x
  27. Langley Richard G., Feldman Steven R., Han Chenglong, Schenkel Brad, Szapary Philippe, Hsu Ming-Chun, Ortonne Jean-Paul, Gordon Kenneth B., Kimball Alexa B., Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial, 10.1016/j.jaad.2009.09.014